nodes	percent_of_prediction	percent_of_DWPC	metapath
Pyrazinamide—AOX1—Methotrexate—lymphatic system cancer	0.39	0.45	CbGbCtD
Pyrazinamide—CYP1A2—Carmustine—lymphatic system cancer	0.224	0.259	CbGbCtD
Pyrazinamide—CYP3A4—Cytarabine—lymphatic system cancer	0.0801	0.0925	CbGbCtD
Pyrazinamide—CYP3A4—Teniposide—lymphatic system cancer	0.0789	0.0911	CbGbCtD
Pyrazinamide—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0552	0.0637	CbGbCtD
Pyrazinamide—CYP3A4—Vincristine—lymphatic system cancer	0.038	0.0439	CbGbCtD
Pyrazinamide—Digestion impaired—Fludarabine—lymphatic system cancer	0.00545	0.0405	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Fludarabine—lymphatic system cancer	0.00393	0.0292	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Fludarabine—lymphatic system cancer	0.00371	0.0276	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Carmustine—lymphatic system cancer	0.00302	0.0224	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Vincristine—lymphatic system cancer	0.0024	0.0178	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Mitoxantrone—lymphatic system cancer	0.00234	0.0174	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Vincristine—lymphatic system cancer	0.00227	0.0169	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Mitoxantrone—lymphatic system cancer	0.00221	0.0164	CcSEcCtD
Pyrazinamide—Dysuria—Fludarabine—lymphatic system cancer	0.00214	0.0159	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00196	0.0146	CcSEcCtD
Pyrazinamide—Anorexia—Mechlorethamine—lymphatic system cancer	0.00191	0.0142	CcSEcCtD
Pyrazinamide—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00174	0.013	CcSEcCtD
Pyrazinamide—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00148	0.011	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00148	0.011	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00145	0.0108	CcSEcCtD
Pyrazinamide—Malaise—Fludarabine—lymphatic system cancer	0.00144	0.0107	CcSEcCtD
Pyrazinamide—Pruritus—Mechlorethamine—lymphatic system cancer	0.00142	0.0106	CcSEcCtD
Pyrazinamide—Anorexia—Teniposide—lymphatic system cancer	0.00141	0.0105	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Methotrexate—lymphatic system cancer	0.0014	0.0104	CcSEcCtD
Pyrazinamide—Arthralgia—Fludarabine—lymphatic system cancer	0.00136	0.0101	CcSEcCtD
Pyrazinamide—Myalgia—Fludarabine—lymphatic system cancer	0.00136	0.0101	CcSEcCtD
Pyrazinamide—Discomfort—Fludarabine—lymphatic system cancer	0.00134	0.00996	CcSEcCtD
Pyrazinamide—Dysuria—Vincristine—lymphatic system cancer	0.00131	0.00971	CcSEcCtD
Pyrazinamide—Decreased appetite—Teniposide—lymphatic system cancer	0.00129	0.00956	CcSEcCtD
Pyrazinamide—Vomiting—Mechlorethamine—lymphatic system cancer	0.00128	0.00948	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.00127	0.00948	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00127	0.00946	CcSEcCtD
Pyrazinamide—Rash—Mechlorethamine—lymphatic system cancer	0.00126	0.0094	CcSEcCtD
Pyrazinamide—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00126	0.0094	CcSEcCtD
Pyrazinamide—Anorexia—Fludarabine—lymphatic system cancer	0.00124	0.00921	CcSEcCtD
Pyrazinamide—Feeling abnormal—Teniposide—lymphatic system cancer	0.00122	0.00906	CcSEcCtD
Pyrazinamide—Nausea—Mechlorethamine—lymphatic system cancer	0.00119	0.00886	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00118	0.0088	CcSEcCtD
Pyrazinamide—Urticaria—Teniposide—lymphatic system cancer	0.00117	0.00873	CcSEcCtD
Pyrazinamide—Body temperature increased—Teniposide—lymphatic system cancer	0.00117	0.00869	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Methotrexate—lymphatic system cancer	0.00116	0.00866	CcSEcCtD
Pyrazinamide—Dyspepsia—Fludarabine—lymphatic system cancer	0.00114	0.00851	CcSEcCtD
Pyrazinamide—Decreased appetite—Fludarabine—lymphatic system cancer	0.00113	0.0084	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00112	0.00834	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Methotrexate—lymphatic system cancer	0.0011	0.00818	CcSEcCtD
Pyrazinamide—Hypersensitivity—Teniposide—lymphatic system cancer	0.00109	0.0081	CcSEcCtD
Pyrazinamide—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00109	0.00809	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00108	0.00806	CcSEcCtD
Pyrazinamide—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00107	0.00796	CcSEcCtD
Pyrazinamide—Malaise—Bleomycin—lymphatic system cancer	0.00105	0.00783	CcSEcCtD
Pyrazinamide—Pruritus—Teniposide—lymphatic system cancer	0.00105	0.00778	CcSEcCtD
Pyrazinamide—Body temperature increased—Fludarabine—lymphatic system cancer	0.00103	0.00764	CcSEcCtD
Pyrazinamide—Myalgia—Bleomycin—lymphatic system cancer	0.000994	0.00739	CcSEcCtD
Pyrazinamide—Discomfort—Bleomycin—lymphatic system cancer	0.000982	0.0073	CcSEcCtD
Pyrazinamide—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000957	0.00712	CcSEcCtD
Pyrazinamide—Vomiting—Teniposide—lymphatic system cancer	0.00094	0.00699	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000933	0.00694	CcSEcCtD
Pyrazinamide—Rash—Teniposide—lymphatic system cancer	0.000932	0.00693	CcSEcCtD
Pyrazinamide—Dermatitis—Teniposide—lymphatic system cancer	0.000931	0.00693	CcSEcCtD
Pyrazinamide—Pruritus—Fludarabine—lymphatic system cancer	0.000919	0.00684	CcSEcCtD
Pyrazinamide—Anorexia—Bleomycin—lymphatic system cancer	0.000908	0.00675	CcSEcCtD
Pyrazinamide—Photosensitivity—Methotrexate—lymphatic system cancer	0.000893	0.00664	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000879	0.00654	CcSEcCtD
Pyrazinamide—Nausea—Teniposide—lymphatic system cancer	0.000878	0.00653	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000868	0.00646	CcSEcCtD
Pyrazinamide—Myalgia—Carmustine—lymphatic system cancer	0.000868	0.00645	CcSEcCtD
Pyrazinamide—Malaise—Mitoxantrone—lymphatic system cancer	0.000854	0.00635	CcSEcCtD
Pyrazinamide—Decreased appetite—Bleomycin—lymphatic system cancer	0.000828	0.00616	CcSEcCtD
Pyrazinamide—Myalgia—Vincristine—lymphatic system cancer	0.000828	0.00616	CcSEcCtD
Pyrazinamide—Vomiting—Fludarabine—lymphatic system cancer	0.000826	0.00614	CcSEcCtD
Pyrazinamide—Rash—Fludarabine—lymphatic system cancer	0.000819	0.00609	CcSEcCtD
Pyrazinamide—Dermatitis—Fludarabine—lymphatic system cancer	0.000819	0.00609	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000814	0.00606	CcSEcCtD
Pyrazinamide—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000807	0.006	CcSEcCtD
Pyrazinamide—Myalgia—Mitoxantrone—lymphatic system cancer	0.000807	0.006	CcSEcCtD
Pyrazinamide—Discomfort—Mitoxantrone—lymphatic system cancer	0.000797	0.00593	CcSEcCtD
Pyrazinamide—Anorexia—Carmustine—lymphatic system cancer	0.000793	0.0059	CcSEcCtD
Pyrazinamide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000785	0.00584	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000777	0.00578	CcSEcCtD
Pyrazinamide—Nausea—Fludarabine—lymphatic system cancer	0.000772	0.00574	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000758	0.00563	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000757	0.00563	CcSEcCtD
Pyrazinamide—Urticaria—Bleomycin—lymphatic system cancer	0.000757	0.00563	CcSEcCtD
Pyrazinamide—Anorexia—Vincristine—lymphatic system cancer	0.000757	0.00563	CcSEcCtD
Pyrazinamide—Body temperature increased—Bleomycin—lymphatic system cancer	0.000753	0.0056	CcSEcCtD
Pyrazinamide—Anorexia—Mitoxantrone—lymphatic system cancer	0.000737	0.00548	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000723	0.00538	CcSEcCtD
Pyrazinamide—Decreased appetite—Carmustine—lymphatic system cancer	0.000723	0.00538	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000718	0.00534	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000704	0.00524	CcSEcCtD
Pyrazinamide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000702	0.00522	CcSEcCtD
Pyrazinamide—Decreased appetite—Vincristine—lymphatic system cancer	0.00069	0.00513	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000685	0.0051	CcSEcCtD
Pyrazinamide—Feeling abnormal—Carmustine—lymphatic system cancer	0.000685	0.0051	CcSEcCtD
Pyrazinamide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000681	0.00506	CcSEcCtD
Pyrazinamide—Pruritus—Bleomycin—lymphatic system cancer	0.000674	0.00501	CcSEcCtD
Pyrazinamide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000672	0.005	CcSEcCtD
Pyrazinamide—Body temperature increased—Carmustine—lymphatic system cancer	0.000658	0.00489	CcSEcCtD
Pyrazinamide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000637	0.00474	CcSEcCtD
Pyrazinamide—Dysuria—Methotrexate—lymphatic system cancer	0.000633	0.00471	CcSEcCtD
Pyrazinamide—Body temperature increased—Vincristine—lymphatic system cancer	0.000628	0.00467	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000618	0.0046	CcSEcCtD
Pyrazinamide—Urticaria—Mitoxantrone—lymphatic system cancer	0.000614	0.00457	CcSEcCtD
Pyrazinamide—Hypersensitivity—Carmustine—lymphatic system cancer	0.000613	0.00456	CcSEcCtD
Pyrazinamide—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000611	0.00455	CcSEcCtD
Pyrazinamide—Vomiting—Bleomycin—lymphatic system cancer	0.000606	0.0045	CcSEcCtD
Pyrazinamide—Rash—Bleomycin—lymphatic system cancer	0.000601	0.00447	CcSEcCtD
Pyrazinamide—Dermatitis—Bleomycin—lymphatic system cancer	0.0006	0.00446	CcSEcCtD
Pyrazinamide—Hypersensitivity—Vincristine—lymphatic system cancer	0.000585	0.00435	CcSEcCtD
Pyrazinamide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00057	0.00424	CcSEcCtD
Pyrazinamide—Nausea—Bleomycin—lymphatic system cancer	0.000566	0.00421	CcSEcCtD
Pyrazinamide—Hepatitis—Methotrexate—lymphatic system cancer	0.000542	0.00403	CcSEcCtD
Pyrazinamide—Vomiting—Carmustine—lymphatic system cancer	0.000529	0.00393	CcSEcCtD
Pyrazinamide—Rash—Carmustine—lymphatic system cancer	0.000524	0.0039	CcSEcCtD
Pyrazinamide—Dermatitis—Carmustine—lymphatic system cancer	0.000524	0.0039	CcSEcCtD
Pyrazinamide—Vomiting—Vincristine—lymphatic system cancer	0.000505	0.00375	CcSEcCtD
Pyrazinamide—Rash—Vincristine—lymphatic system cancer	0.000501	0.00372	CcSEcCtD
Pyrazinamide—Dermatitis—Vincristine—lymphatic system cancer	0.0005	0.00372	CcSEcCtD
Pyrazinamide—Nausea—Carmustine—lymphatic system cancer	0.000494	0.00367	CcSEcCtD
Pyrazinamide—Vomiting—Mitoxantrone—lymphatic system cancer	0.000492	0.00366	CcSEcCtD
Pyrazinamide—Rash—Mitoxantrone—lymphatic system cancer	0.000488	0.00363	CcSEcCtD
Pyrazinamide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000487	0.00362	CcSEcCtD
Pyrazinamide—Nausea—Vincristine—lymphatic system cancer	0.000472	0.00351	CcSEcCtD
Pyrazinamide—Nausea—Mitoxantrone—lymphatic system cancer	0.000459	0.00342	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000438	0.00326	CcSEcCtD
Pyrazinamide—Malaise—Methotrexate—lymphatic system cancer	0.000426	0.00317	CcSEcCtD
Pyrazinamide—Myalgia—Methotrexate—lymphatic system cancer	0.000402	0.00299	CcSEcCtD
Pyrazinamide—Arthralgia—Methotrexate—lymphatic system cancer	0.000402	0.00299	CcSEcCtD
Pyrazinamide—Discomfort—Methotrexate—lymphatic system cancer	0.000397	0.00295	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000377	0.0028	CcSEcCtD
Pyrazinamide—Anorexia—Methotrexate—lymphatic system cancer	0.000367	0.00273	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000351	0.00261	CcSEcCtD
Pyrazinamide—Dyspepsia—Methotrexate—lymphatic system cancer	0.000339	0.00252	CcSEcCtD
Pyrazinamide—Decreased appetite—Methotrexate—lymphatic system cancer	0.000335	0.00249	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000333	0.00247	CcSEcCtD
Pyrazinamide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000317	0.00236	CcSEcCtD
Pyrazinamide—Urticaria—Methotrexate—lymphatic system cancer	0.000306	0.00228	CcSEcCtD
Pyrazinamide—Body temperature increased—Methotrexate—lymphatic system cancer	0.000305	0.00226	CcSEcCtD
Pyrazinamide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000284	0.00211	CcSEcCtD
Pyrazinamide—Pruritus—Methotrexate—lymphatic system cancer	0.000273	0.00203	CcSEcCtD
Pyrazinamide—Vomiting—Methotrexate—lymphatic system cancer	0.000245	0.00182	CcSEcCtD
Pyrazinamide—Rash—Methotrexate—lymphatic system cancer	0.000243	0.00181	CcSEcCtD
Pyrazinamide—Dermatitis—Methotrexate—lymphatic system cancer	0.000243	0.0018	CcSEcCtD
Pyrazinamide—Nausea—Methotrexate—lymphatic system cancer	0.000229	0.0017	CcSEcCtD
